New pneumococcal vaccine to come from Biovac
The goal is to better produce a vaccine to protect the body from bacteria that cause pneumonia, namely Prevenar 13. This vaccine is effective in protecting children between the ages of 6 weeks and 5 years old from pneumococcal infections. The vaccine is also effective for adults who are 50 and older.
Under the agreement, Prevenar 13 will be produced at a new commercial-scale facility located in Cape Town. The facility is owned by BioVac.
"Preventing pneumococcal disease is a priority for Pfizer in South Africa,” Jennifer Power, the South African Country Manager for Pfizer Inc., said. “We have already seen great results since vaccination was introduced and we are pleased to partner with Biovac, sharing best practices, knowledge and skills to continue to make a real difference for patients.”
This move will strengthen the relations between South Africa, Pfizer and BioVac.
“We are confident that this partnership will help ensure the sustainable supply of our pneumococcal conjugate vaccine for patients in South Africa,” Power said.